FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2037758905> ?p ?o ?g. }

• W2037758905 abstract "Approximately 70% of all patients with myelodysplastic syndrome (MDS) present with lower-risk disease. Some of these patients will initially respond to treatment with growth factors to improve anemia but will eventually cease to respond, while others will be resistant to growth factor therapy. Eventually, all lower-risk MDS patients require multiple transfusions and long-term therapy. While some patients may respond briefly to hypomethylating agents or lenalidomide, the majority will not, and new therapeutic options are needed for these lower-risk patients. Our previous clinical trials with ezatiostat (ezatiostat hydrochloride, Telentra®, TLK199), a glutathione S-transferase P1-1 inhibitor in clinical development for the treatment of low- to intermediate-risk MDS, have shown significant clinical activity, including multilineage responses as well as durable red-blood-cell transfusion independence. It would be of significant clinical benefit to be able to identify patients most likely to respond to ezatiostat before therapy is initiated. We have previously shown that by using gene expression profiling and grouping by response, it is possible to construct a predictive score that indicates the likelihood that patients without deletion 5q will respond to lenalidomide. The success of that study was based in part on the fact that the profile for response was linked to the biology of the disease. RNA was available on 30 patients enrolled in the trial and analyzed for gene expression on the Illumina HT12v4 whole genome array according to the manufacturer’s protocol. Gene marker analysis was performed. The selection of genes associated with the responders (R) vs. non-responders (NR) phenotype was obtained using a normalized and rescaled mutual information score (NMI). We have shown that an ezatiostat response profile contains two miRNAs that regulate expression of genes known to be implicated in MDS disease pathology. Remarkably, pathway analysis of the response profile revealed that the genes comprising the jun-N-terminal kinase/c-Jun molecular pathway, which is known to be activated by ezatiostat, are under-expressed in patients who respond and over-expressed in patients who were non-responders to the drug, suggesting that both the biology of the disease and the molecular mechanism of action of the drug are positively correlated." @default.
• W2037758905 created "2016-06-24" @default.
• W2037758905 creator A5017114712 @default.
• W2037758905 creator A5050290665 @default.
• W2037758905 creator A5056395840 @default.
• W2037758905 creator A5063108270 @default.
• W2037758905 creator A5071920263 @default.
• W2037758905 creator A5077622597 @default.
• W2037758905 creator A5087963156 @default.
• W2037758905 date "2012-05-06" @default.
• W2037758905 modified "2023-10-16" @default.
• W2037758905 title "Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome" @default.
• W2037758905 cites W1648301895 @default.
• W2037758905 cites W187238933 @default.
• W2037758905 cites W1969008341 @default.
• W2037758905 cites W1981904952 @default.
• W2037758905 cites W1988072810 @default.
• W2037758905 cites W2001421157 @default.
• W2037758905 cites W2021333892 @default.
• W2037758905 cites W2031980017 @default.
• W2037758905 cites W2066053804 @default.
• W2037758905 cites W2075379915 @default.
• W2037758905 cites W2081279521 @default.
• W2037758905 cites W2084120869 @default.
• W2037758905 cites W2084897544 @default.
• W2037758905 cites W2090184439 @default.
• W2037758905 cites W2096258302 @default.
• W2037758905 cites W2106584820 @default.
• W2037758905 cites W2114492363 @default.
• W2037758905 cites W2119609551 @default.
• W2037758905 cites W2121401558 @default.
• W2037758905 cites W2123879591 @default.
• W2037758905 cites W2129510594 @default.
• W2037758905 cites W2130410032 @default.
• W2037758905 cites W2140855509 @default.
• W2037758905 cites W2144221002 @default.
• W2037758905 cites W2150892663 @default.
• W2037758905 cites W2154951934 @default.
• W2037758905 cites W2160098916 @default.
• W2037758905 cites W2163587546 @default.
• W2037758905 doi "https://doi.org/10.1186/1756-8722-5-20" @default.
• W2037758905 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3407785" @default.
• W2037758905 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22559819" @default.
• W2037758905 hasPublicationYear "2012" @default.
• W2037758905 type Work @default.
• W2037758905 sameAs 2037758905 @default.
• W2037758905 citedByCount "17" @default.
• W2037758905 countsByYear W20377589052012 @default.
• W2037758905 countsByYear W20377589052013 @default.
• W2037758905 countsByYear W20377589052014 @default.
• W2037758905 countsByYear W20377589052015 @default.
• W2037758905 countsByYear W20377589052017 @default.
• W2037758905 countsByYear W20377589052018 @default.
• W2037758905 countsByYear W20377589052019 @default.
• W2037758905 countsByYear W20377589052020 @default.
• W2037758905 countsByYear W20377589052022 @default.
• W2037758905 countsByYear W20377589052023 @default.
• W2037758905 crossrefType "journal-article" @default.
• W2037758905 hasAuthorship W2037758905A5017114712 @default.
• W2037758905 hasAuthorship W2037758905A5050290665 @default.
• W2037758905 hasAuthorship W2037758905A5056395840 @default.
• W2037758905 hasAuthorship W2037758905A5063108270 @default.
• W2037758905 hasAuthorship W2037758905A5071920263 @default.
• W2037758905 hasAuthorship W2037758905A5077622597 @default.
• W2037758905 hasAuthorship W2037758905A5087963156 @default.
• W2037758905 hasBestOaLocation W20377589051 @default.
• W2037758905 hasConcept C104317684 @default.
• W2037758905 hasConcept C126322002 @default.
• W2037758905 hasConcept C143998085 @default.
• W2037758905 hasConcept C150194340 @default.
• W2037758905 hasConcept C190727270 @default.
• W2037758905 hasConcept C194409129 @default.
• W2037758905 hasConcept C2776063141 @default.
• W2037758905 hasConcept C2776239401 @default.
• W2037758905 hasConcept C2779134260 @default.
• W2037758905 hasConcept C2780007613 @default.
• W2037758905 hasConcept C2780401358 @default.
• W2037758905 hasConcept C2780817109 @default.
• W2037758905 hasConcept C535046627 @default.
• W2037758905 hasConcept C55493867 @default.
• W2037758905 hasConcept C60644358 @default.
• W2037758905 hasConcept C71924100 @default.
• W2037758905 hasConcept C86803240 @default.
• W2037758905 hasConceptScore W2037758905C104317684 @default.
• W2037758905 hasConceptScore W2037758905C126322002 @default.
• W2037758905 hasConceptScore W2037758905C143998085 @default.
• W2037758905 hasConceptScore W2037758905C150194340 @default.
• W2037758905 hasConceptScore W2037758905C190727270 @default.
• W2037758905 hasConceptScore W2037758905C194409129 @default.
• W2037758905 hasConceptScore W2037758905C2776063141 @default.
• W2037758905 hasConceptScore W2037758905C2776239401 @default.
• W2037758905 hasConceptScore W2037758905C2779134260 @default.
• W2037758905 hasConceptScore W2037758905C2780007613 @default.
• W2037758905 hasConceptScore W2037758905C2780401358 @default.
• W2037758905 hasConceptScore W2037758905C2780817109 @default.
• W2037758905 hasConceptScore W2037758905C535046627 @default.
• W2037758905 hasConceptScore W2037758905C55493867 @default.
• W2037758905 hasConceptScore W2037758905C60644358 @default.
• W2037758905 hasConceptScore W2037758905C71924100 @default.
• W2037758905 hasConceptScore W2037758905C86803240 @default.

• next